-
Reply
Dieckman, T., Schumann, M., Beaumont, H. & RCDII Tofacitinib Consortium, Mar 2025, In: Clinical Gastroenterology and Hepatology. 23, 4, p. 679-680 2 p.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
-
Activated CD27+PD-1+ CD8 T Cells and CD4 T Regulatory Cells Dominate the Tumor Microenvironment in Refractory Celiac Disease Type II
Dieckman, T., Schreurs, M., Lindelauf, C., Mahfouz, A., Meijer, C. R., Pigeaud, L., van Unen, V., Bouma, G. & Koning, F., 1 Jan 2025, In: Gastro Hep Advances. 4, 1, 100545.Research output: Contribution to journal › Article* › Academic › peer-review
-
Enduring Clinical Remission in Refractory Celiac Disease Type II with Tofacitinib: An Open-Label Clinical Study
Dieckman, T., Schumann, M., Beaumont, H., Bontkes, H. J., Koning, F., Bouma, G., Byrnes, V., McCarthy, J., Neefjes-Borst, A., Loddenkemper, C., van Bergen, J., Weegh, M. O. D. & RCDII Tofacitinib Consortium, Nov 2024, In: Clinical Gastroenterology and Hepatology. 22, 11, p. 2334-2336 3 p.Research output: Contribution to journal › Short survey* › Academic › peer-review
- All publications
